COLLEGIUM PHARMACEUTICAL, INC

The company is a diversified biopharmaceutical company focused on improving the lives of people with serious medical conditions. It develops, licenses, and acquires differentiated products for attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. The company commercializes its products in the United States. Key products include Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively "Nucynta Products"), and Symproic. Jornay PM is a central nervous system (CNS) stimulant prescription medicine containing methylphenidate HCl, a Schedule II methylphenidate. It was approved by the U.S. Food and Drug Administration (FDA) in August 2018 for treating ADHD in people six years of age and older. Jornay PM is currently the only FDA-approved stimulant medication dosed in the evening. The company acquired Ironshore, which developed Jornay PM, on September 3, 2024, expanding its business into neuropsychiatry via the ADHD market. Belbuca is a buccal film containing buprenorphine, a Schedule III opioid. It was FDA-approved in October 2015 for severe and persistent pain requiring extended daily opioid analgesic treatment when other options are inadequate. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone, a Schedule II opioid. It uses the DETERx technology platform, which combines an active opioid ingredient with a fatty acid and waxes to form microspheres in a capsule. These wax-based microspheres are designed to resist particle size reduction and dose dumping when physically and chemically manipulated, aiming to deter abuse and misuse like crushing, chewing, heating, and injecting.